• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

    3/24/25 5:03:10 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRLD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Vaddi Krishna

    (Last) (First) (Middle)
    C/O PRELUDE THERAPEUTICS INCORPORATED
    175 INNOVATION BOULEVARD

    (Street)
    WILMINGTON DE 19805

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Prelude Therapeutics Inc [ PRLD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/20/2025 P 5,416 A $0.7294(1) 1,309,296 D
    Common Stock 03/21/2025 P 15,000 A $0.7306(2) 1,324,296 D
    Common Stock 423,655 I By Trust(3)
    Common Stock 551,774 I By Trust(4)
    Common Stock 551,776 I By Trust(5)
    Common Stock 142,553 I See footnote(6)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7294 to $0.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
    2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73 to $0.731, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
    3. The Reporting Person is a beneficiary of the Dolphin City Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    4. The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    5. The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    6. The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    Remarks:
    /s/ Bryant D. Lim, Attorney-in-Fact 03/24/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRLD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRLD

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00Neutral → Buy
    H.C. Wainwright
    6/20/2024$3.00Equal Weight → Underweight
    Barclays
    3/13/2024$7.00Mkt Outperform
    JMP Securities
    2/20/2024$5.00Buy → Neutral
    H.C. Wainwright
    12/19/2023$10.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    11/21/2022$8.00 → $6.00Neutral → Underperform
    BofA Securities
    9/9/2022$19.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    7/29/2022$9.00Buy
    Jefferies
    More analyst ratings

    $PRLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prelude Therapeutics Announces Strategic Business Update

    Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN

    11/4/25 7:05:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

    Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net salesPrelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte would lead development and commercialization globally WILMINGTON, Del., Nov. 04, 2025

    11/4/25 7:01:00 AM ET
    $INCY
    $PRLD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

    WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company's JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in Orlando, FL December 6-9, 2025. The abstracts can be found on the ASH 2025 website ASH Annual Meeting & Exposition - Hematology.org. "We are excited for the opportunity to share the first-time disclosure of

    11/3/25 9:01:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Dorton Katina

    3 - Prelude Therapeutics Inc (0001678660) (Issuer)

    10/20/25 4:01:15 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CMO Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,355 shares, increasing direct ownership by 7% to 86,917 units (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    10/7/25 7:05:37 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CMO Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,355 shares, increasing direct ownership by 8% to 80,897 units (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    7/8/25 4:06:56 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    SEC Filings

    View All

    Prelude Therapeutics Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Prelude Therapeutics Inc (0001678660) (Filer)

    11/4/25 8:53:18 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Prelude Therapeutics Inc (0001678660) (Filer)

    10/17/25 7:40:32 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Incorporated filed SEC Form 8-K: Other Events

    8-K - Prelude Therapeutics Inc (0001678660) (Filer)

    9/19/25 7:41:30 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    3/27/25 4:40:54 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    3/27/25 4:37:44 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    3/24/25 5:03:10 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00

    9/19/24 7:51:24 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00

    6/20/24 7:37:20 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Prelude Therapeutics with a new price target

    JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00

    3/13/24 7:41:41 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Leadership Updates

    Live Leadership Updates

    View All

    Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

    WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. "Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We welcome her to our board and we look forward to

    10/17/25 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

    Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu

    5/10/22 8:00:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Reports Full Year 2021 Financial Results

    Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and continued advancement of Prelude's diverse precision oncology pipeline Cash runway guidance extended to 2H/2024 WILMINGTON, Del., March 16, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021. "With Prelude's core competencies in cancer biology an

    3/16/22 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Financials

    Live finance-specific insights

    View All

    Prelude Therapeutics Announces Strategic Business Update

    Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN

    11/4/25 7:05:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

    -  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation -  At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events -  Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical

    9/13/24 10:00:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

    PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of an abstract regarding PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 taking place in Barcelona, Spain September 13-17, 2024. The abstract can be found on the ESMO 2024 website

    9/9/24 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

    2/13/24 1:34:34 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

    2/12/24 5:30:07 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

    2/12/24 4:26:50 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care